AMLX
Amylyx Pharmaceuticals, Inc.
1.76
-
0.02
1.12%
10 x 1.72
12 x 1.77
bid
ask
11 @ 04:00 PM
1.84+0.08 (4.55%)
Bearish
1
Bullish
7
sentiment
1.70
day range
1.84
1.76
52 week range
30.10
Prev Close1.78
Open1.79
Low1.70
High1.84
Volume5.20M
Avg. Volume3.34M
Market Cap119.69M
Inst. Own104.34%
Beta-0.93
Short Ratio2.43
Div & Yield0.00 /
EPS0.70
P/E2.51
1yr Target4.25
50day MA7.43
200day MA15.06
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | 0.24 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | 0.2 | 0.07 | -0.13 | -65.00% |
2023-11-09 | 2023-09 | 0.42 | 0.3 | -0.12 | -28.57% |
2023-11-09 | 2023-09 | 0.42 | N/A | N/A | N/A |
2023-08-10 | 2023-06 | 0.01 | N/A | N/A | N/A |
2023-08-10 | 2023-06 | 0.01 | 0.31 | 0.3 | 3000.00% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-23 | Goldman Sachs | Upgrade | Neutral | Buy |
2023-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-14 | Mizuho | Upgrade | Buy | Buy |
2023-05-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-15 | BEDROSIAN CAMILLE L | Officer | 155.24K | Stock Award(Grant) |
2024-04-15 | COHEN JOSHUA BARRY | Chief Executive Officer | 3.20M | Stock Award(Grant) |
2023-12-14 | FIRESTONE KAREN M. | Director | 5.00K | Purchase |
2024-04-15 | FRATES JAMES MATTHEW | Chief Financial Officer | 252.50K | Stock Award(Grant) |
2024-04-15 | KLEE JUSTIN B | Chief Executive Officer | 3.14M | Stock Award(Grant) |
2024-04-15 | MAZZARIELLO GINA | Officer | 161.93K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 4.93M | 106.25M | 7.31% |
2023-06-29 | Perceptive Advisors Llc | 4.87M | 105.13M | 7.23% |
2023-06-29 | Blackrock Inc. | 3.51M | 75.61M | 5.20% |
2023-06-29 | Viking Global Investors, L.P. | 2.96M | 63.90M | 4.40% |
2023-06-29 | Boxer Capital, LLC | 2.08M | 44.95M | 3.09% |
2023-06-29 | Marshall Wace LLP | 1.98M | 42.71M | 2.94% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.66M | 35.78M | 2.46% |
2023-06-29 | Vanguard Small-Cap Index Fund | 1.39M | 29.93M | 2.06% |
2023-08-30 | iShares Russell 2000 ETF | 1.16M | 24.98M | 1.72% |
2023-06-29 | Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.12M | 24.09M | 1.66% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 794.61K | 17.14M | 1.18% |
2023-07-30 | Federated Hermes Kaufmann Fund | 774.64K | 18.17M | 1.15% |
Dividend
...
Dividend | Date |
---|---|
0.42 | 2018-03-28 |
0.36 | 2017-12-28 |
0.24 | 2017-09-28 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Amylyx's ALS drug fails in late-stage confirmatory study
reuters.com • -
The Top 3 Biotech Stocks to Buy in March 2024
investorplace.com • -
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
investorplace.com • -
Get Rich Quick With These 3 Biotech Stocks to Buy Now
investorplace.com • -
3 small-cap biotechs with potential breakthroughs in 2024
marketbeat.com • -
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
investorplace.com • -
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
investorplace.com • -
7 Healthcare Stocks Taking Medicine to the Next Level
investorplace.com • -
2 Biotech Stocks With Huge Catalysts in 2024
fool.com • -
Amylyx Therapeutics shares could soar if upcoming ALS trial succeeds, analysts say
proactiveinvestors.com • -
Is Amylyx (AMLX) Stock a Solid Choice Right Now?
zacks.com • -
These biotechs targeting multiple neurodegenerative diseases
marketbeat.com • -
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
investorplace.com • -
Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector
seekingalpha.com • -
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
Amylyx Pharmaceuticals's ALS dug rejected again by EU regulators
proactiveinvestors.com • -
EU regulator declines to recommend Amylyx' ALS drug
reuters.com • -
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
investorplace.com • -
3 Biotech Stocks to Buy Before Drug Trials End
investorplace.com • -
Amylyx Pharmaceuticals: Post Q1 Selloff Appears Overdone
seekingalpha.com • -
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
marketbeat.com • -
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2023 Earnings Call Transcript
seekingalpha.com • -
Final Trades: IBM, Exxon Mobil, Amylyx, and Home Depot
youtube.com • -
3 Biotechs That Might Get Bought Out in 2023
fool.com • -
7 Biotech Stocks to Buy for 100% Returns
investorplace.com • -
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
These Are the Top 10 Holdings of David Kim
247wallst.com • -
Amylyx: Patient Advocacy, If Not Drug Merit, Will See It Through
seekingalpha.com • -
Amylyx: Future Looks Good After Surprise Approval, But Unpredictable, Too
seekingalpha.com • -
These Are the 10 Best-Performing IPOs in 2022 Through October
247wallst.com • -
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Amylyx's ALS Drug Is Approved by the FDA
barrons.com • -
Amylyx's ALS drug wins FDA approval despite questionable data
marketwatch.com • -
3 IPO Stocks That You Want to Own
fool.com • -
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today?
investorplace.com • -
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug
investorplace.com • -
4 Top Biotech Stocks To Watch Today
stockmarket.com • -
Here's How Citi Views Amylyx Pharma
benzinga.com • -
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
investorplace.com • -
Amylyx's ALS Drug Application Hangs In The Balance
seekingalpha.com • -
7 Biotech Stocks With Key Catalysts in March
investorplace.com • -
Andreas Halvorsen Gets in on Amylyx Pharmaceuticals' IPO
gurufocus.com • -
U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week
seekingalpha.com • -
2022 IPO Market Kicks Off With 3 Biotechs Set To Trade On Friday
seekingalpha.com •